Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2318 |
Sacubitril/Valsartan
Sacubitril mixture with Valsartan,沙库必曲/缬沙坦,Valsartan,Sacubitril,LCZ696 |
Apoptosis; RAAS; Neprilysin | Apoptosis; Endocrinology/Hormones; Metabolism |
Sacubitril/Valsartan (LCZ696),以1:1摩尔比由Valsartan(一种ARB)和Sacubitril(AHU377)组成,为创新口服血管紧张素受体-脑啡肽酶(ARN)双重抑制剂,旨在治疗高血压与心力衰竭。其作用机制包括抑制炎症、氧化应激及细胞凋亡,有助于改善糖尿病心肌病。 | |||
TP2045 |
CH 275
|
||
Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens | |||
T4200 |
Sacubitril hemicalcium salt
AHU-377 (hemicalcium salt),LCZ696中间体,AHU377 calcium salt |
Neprilysin | Metabolism |
Sacubitril hemicalcium salt (AHU377 calcium salt) 是一种有效的 NEP 抑制剂,IC50=5 nM。它是研究心力衰竭药物 LCZ696 的组分之一。 | |||
T13125 | TD-0212 | Others | Others |
TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). | |||
T13125L | TD-0212 TFA | Others | Others |
TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). | |||
T4574L |
Sacubitril sodium
AHU377,AHU-377,LCZ696,AHU 377 |
||
Sacubitril is an angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. | |||
T71118 | NEP-28 | ||
NEP-28 is an AR agonist. NEP28 is a new SARM exhibiting high selectivity for androgen receptor. NEP28 showed tissue-selective effect equivalent to or higher than existing SARMs. In addition, the administration of NEP28 increased the activity of neprilysin, a known Aβ-degrading enzyme. |